Table 4A.
Clinical trials of CD40L agonist therapy
| Drug | Feature | Phase | Disease | Outcome | PMID/Identifier |
|---|---|---|---|---|---|
| Avrend | Trimeric soluble human CD40L | 1 | Advanced solid tumors and NHL | Safe; Effective | 11432896 |
| Ad-CD40L | Adenovirus carrying human CD40L gene | 1, 2 | Melanoma | Safe; Effective | 27031851 28427434 |
| 1/2 | Bladder cancer | Safe; Effective | 20448220 | ||
| Ad-CD40L-CLL cells | Autologous CLL cells transduced with Ad-murine or humanized CD40L | 1 | CLL | Safe; Effective | 11049967 20882050 |
| GM.CD40L | Bystander cells expressing liuman GM-CSF/CD40L | 2 | Refectory lung adenocarcinoma | Safe | 23994887 |
| 1/2 | Advanced lung adenocarcinoma | Safe | 30209589 | ||
| TriMixDC | Autologous DC electroporated with human CD40L/TLR4/ CD70 mRNA | 1 | Advanced melanoma | Safe | 21577140 |
| TriMixDC-MEL | Autologous DC electroporated with human CD40L/TLR4/ CD70/tumor antigen mRNA | 1 | Advanced melanoma | Safe | 23904461 |
| 2 | Melanoma | Unpublished |
NCT00101166 |
Abbreviations: CD40L, CD40L ligand; CLL, chronic lymphocytic leukemia; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; NHL, non-Hodgkin lymphoma; TLR4, toll like receptor 4.